Manager I, R2R Operations at Bristol-Myers Squibb

Hyderabad, Telangana, India

Bristol-Myers Squibb Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

Requirements

Candidates require a minimum of 5-7 years of experience, or 8+ years for non-CA/CMA professionals, with exceptional expertise in record-to-report accounting processes and a deep understanding of the business landscape, market trends, and industry dynamics. Excellent leadership skills are essential for inspiring and motivating team members.

Responsibilities

The R2R Ops Manager will support the execution of R2R accounting activities in the Hyderabad CoE, performing period-end close activities such as account reconciliation QC, accounts receivable, accruals, and operational reporting. Responsibilities include monitoring and managing month-end, quarter-end, and year-end activities, preparing balance sheet control reconciliations, managing internal customer satisfaction, completing audits, preparing management-level reports, executing disaster recovery activities, and undertaking ad-hoc projects. The role also involves holding oneself and others accountable for timelines, quality, and accuracy, articulating material risks and opportunities, and actively participating in designing and executing response or contingency plans.

Skills

Record-to-Report (R2R) accounting
Financial accounting
Leadership
Team Management
Communication
Problem-Solving

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI